已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

411 INNATE: immunotherapy during neoadjuvant therapy for rectal cancer to elucidate local and systemic therapeutic responses

福克斯 医学 结直肠癌 肿瘤科 放射治疗 化疗 癌症 内科学 新辅助治疗 临床试验 免疫疗法 外科 乳腺癌 奥沙利铂
作者
Nina N. Sanford,Eslam A. Elghonaimy,Adel Kardosh,Syed Mohammad Ali Kazmi,Javier Salgado Pogacnik,Xiaodong Yang,Robert Timmerman,Todd A. Aguilera
出处
期刊: 卷期号:: A442-A442 被引量:2
标识
DOI:10.1136/jitc-2021-sitc2021.411
摘要

Background

The relative risk of developing rectal cancer has quadrupled in young adults over the last 40 years and approximately 50% of patients develop recurrence within 3 years. Thus, there is a critical need for new approaches to improve survival but cancer Immunotherapy has had little impact on colorectal cancer. The anti-CD40 agonist immunotherapy is emerging and APX005M has shown promise in phase I and ongoing phase II trials. Anti-CD40 can stimulate both innate and adaptive immune responses and a greater response can be achieved combining anti-CD40 with radiation therapy (RT) in animal models. We developed the INNATE trial, a phase II randomized trial of neoadjuvant short course RT followed by chemotherapy with or without the addition of APX005M for rectal cancer (NCT04130854).

Methods

The INNATE trial is a multi-center, 58 patient, 3:2 randomization clinical trial, that adds APX005M to short course RT (SCRT) and subsequent FOLFOX chemotherapy prior to definitive radiation. Eligibility includes stage III and high risk stage II rectal cancer and candidates for standard neoadjuvant therapy and no contraindications for immunotherapy or radiation. Patients receive 5Gy x 5 fractions over five days and if randomized to experimental arm will receive APX005M on day 3 of radiation. After a two week break patients receive an optional endoscopy and biopsy followed by standard FOLFOX chemotherapy with APX005M infusion after disconnection of 5-FU chemotherapy pump. Study arm receives APX005M with 5 of 6 cycles of FOLFOX. After treatment patients undergo restating, endoscopy, and trans abdominal resection. The primary endpoint is pathologic complete response with the null estimated to be 20% and alternative 50% for a power of 0.8 and type 1 error of 0.1. Secondary endpoints include overall survival, toxicity analysis, and disease free survival. For correlative analysis, tissue is collected pre-treatment, two weeks after RT, and at surgery, then blood collected during treatment and at follow up.

Results

To date 16 patients have been randomized and initiated treatment. The treatment is well tolerated. Fiveteen patients received pre- and post-SCRT biopsies. The study team plans correlative analysis including single cell RNA sequencing, multiplex imunohistochemistry, and bulk sequencing. Preliminary data shows changes in the immune tumor microenvironment from patients treated as their own control and between SCRT versus SCRT + APX00M.

Conclusions

The INNATE trial shows feasibility of incorporating novel immunotherapies with an emerging standard of care incorporating short course RT. It serves as an important platform for scientific and clinical investigation.

Trial Registration

Clinicaltrials

gov: NCT04130854

Ethics Approval

The clinical trial has institutional review board approval at the University of Texas Southwestern, Oregon Health and Sciences University, Wake Forest, and Moffitt. All patients have provided informed consent.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zilch完成签到,获得积分10
刚刚
drhkc完成签到,获得积分10
1秒前
积极问晴完成签到,获得积分10
2秒前
YIDAN发布了新的文献求助20
2秒前
贾茜茜完成签到 ,获得积分10
2秒前
极限001的应助被Nics110采纳,获得200
3秒前
LWY完成签到 ,获得积分10
4秒前
桃子完成签到 ,获得积分10
5秒前
好幸运发布了新的文献求助10
5秒前
6秒前
医学完成签到,获得积分10
7秒前
Zilch发布了新的文献求助10
7秒前
华仔的应助被Evan采纳,获得10
7秒前
板栗南瓜完成签到 ,获得积分10
8秒前
han完成签到,获得积分10
9秒前
9秒前
9秒前
佳1完成签到,获得积分20
11秒前
11秒前
rin382完成签到,获得积分10
11秒前
1111发布了新的文献求助10
12秒前
12秒前
德力达完成签到,获得积分20
13秒前
13秒前
orixero的应助被雾里采纳,获得10
13秒前
13秒前
略略发布了新的文献求助10
14秒前
尊敬诗桃完成签到 ,获得积分10
14秒前
李健的应助被lll采纳,获得10
15秒前
18秒前
小波发布了新的文献求助30
18秒前
浩whu完成签到,获得积分10
19秒前
七叶花开完成签到,获得积分10
20秒前
奥特曼打小人的应助被YIDAN采纳,获得20
20秒前
rin382发布了新的文献求助50
20秒前
冰魄落叶完成签到,获得积分10
21秒前
21秒前
华无剑的应助被萧雨墨采纳,获得10
21秒前
念槿完成签到,获得积分10
22秒前
健壮的含卉完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158391
求助须知:如何正确求助?哪些是违规求助? 9554206
关于积分的说明 21718287
捐赠科研通 7747762
什么是DOI,文献DOI怎么找? 3426964
关于科研通互助平台的介绍 2551704
邀请新用户注册赠送积分活动 2471132